AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01332578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Test product
Study NCT01332578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Test product
Study NCT03001219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti-TNF-alpha
Description: Participants will continue their pre-trial anti-TNF-alpha therapy at a stable dose.
Study NCT03001219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-TNF-alpha
Description: Participants will continue their pre-trial anti-TNF-alpha therapy at a stable dose.
Study NCT03001219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Participants will continue their pre-trial methotrexate therapy at a stable dose.
Study NCT03001219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Participants will continue their pre-trial methotrexate therapy at a stable dose.
Study NCT03001219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive intravenous infusion of placebo.
Study NCT03001219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7123520
Description: Participants will receive intravenous infusion of RO7123520.
Study NCT01425723 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rFIXFc
Description: Administered as specified in the treatment arm.
Study NCT04002505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concussion and Brain Bleed App (CBB)
Description: Tablet based decision aid that encourages shared decision making with the goal of educating patients to reduce unnecessary CT scans
Study NCT00446199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5mg DRSP / 0.5mg E2 (BAY86-4891)
Description: One tablet \[0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 3 cycles (28 days per cycle).
Study NCT00446199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25mg DRSP / 0.5mg E2 (BAY86-4891)
Description: One tablet \[0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 3 cycles (28 days per cycle).
Study NCT00446199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol (E2 0.3mg)
Description: One tablet \[17β-estradiol (E2 0.3mg)\] per day taken orally for 3 cycles (28 days per cycle).
Study NCT00446199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).
Study NCT02426047 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: betaquik®
Description: Participants will add betaquik® (a liquid emulsion of medium chain triglycerides) for a 10 day time interval starting 2 days prior to and encompassing the primary catamenial pattern.
Study NCT01481909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rupatadin
Description: 20 mg, 28 days over 60 days
Study NCT04163640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intra-ovarian platelet rich plasma injection
Description: patients will undergo a transvaginal intra-ovarian platelet rich plasma injection
Study NCT01011075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Description: Imatinib (Gleevec) 600 mg/day, oral administration in 4-day pulses(days 1-4; 8-11; 15-18) Cycle length: 28 days Number of cycles: up to 6
Study NCT01011075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 90 mg/m2 IV on days 3, 10, 17 Cycle length: 28 days Number of cycles: up to 6
Study NCT03708965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR-141
Description: IV infusion (lyophilized powder)
Study NCT00946348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Dronabinol 10 mg or 15 mg
Study NCT00946348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabis
Description: Cannabis cigarette
Study NCT03867799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Immunotherapy
Study NCT04232813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol 10 MCG Vaginal Tablet [VAGIFEM]
Description: To insert the tablets the patient must use the applicator provided in the way explained in the prospectus.
Study NCT04232813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Promestriene Vaginal
Description: To insert the cream the patient must use the applicator provided in the way explained in the prospectus.
Study NCT02171676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT02171676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Study NCT02799030 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BF-200 ALA 1%
Description: topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
Study NCT02799030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF-200 ALA 1%
Description: topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
Study NCT02799030 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BF-200 ALA 3%
Description: topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
Study NCT02799030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF-200 ALA 3%
Description: topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
Study NCT02799030 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BF-200 ALA 10%
Description: topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
Study NCT02799030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF-200 ALA 10%
Description: topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
Study NCT01264042 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous Sulfate
Description: 60 mg with 200 mL water, single administration
Study NCT00570882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib 2/1
Description: Sunitinib 50 mg PO 2 weeks followed by 1 week rest
Study NCT02753738 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Association re-learning paradigm
Description: 21 daily internet-based sessions (20min) of learning new associations (pairs) of stimuli performed during escitalopram/placebo treatment
Study NCT02753738 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Association re-learning paradigm
Description: 21 daily internet-based sessions (20min) of learning new associations (pairs) of stimuli performed during escitalopram/placebo treatment
Study NCT02009228 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ovarian cystectomy
Study NCT02831361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin
Study NCT02831361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemigliptin placebo
Study NCT02831361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: For patients who have been taking metformin, the patients who had taken at least 1000 mg of metformin daily and continue the same dosage and administration as before participant in the study
Study NCT02831361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: For patients who have been taking metformin, the patients who had taken at least 1000 mg of metformin daily and continue the same dosage and administration as before participant in the study
Study NCT02831361 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diet/exercise questionnaire
Description: doing exercise with about intermediate intensity(50\~70%) for ≥150minutes in total over at least 3 times(every other day) weekly should be recommended and regualr diet without greater changes in life style as much as possible during the whole study period.~the questionnaire regarding diet/exercise will be collected at -week2, week 1 week 7, week 13, week 19, week 25
Study NCT02831361 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Diet/exercise questionnaire
Description: doing exercise with about intermediate intensity(50\~70%) for ≥150minutes in total over at least 3 times(every other day) weekly should be recommended and regualr diet without greater changes in life style as much as possible during the whole study period.~the questionnaire regarding diet/exercise will be collected at -week2, week 1 week 7, week 13, week 19, week 25
Study NCT03210454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smallholder Marketing
Description: The smallholder marketing intervention involves product purchasing (e.g., bananas, beans, goats, eggs) from smallholder farmers' associations through WFP's large procurement procedures. WFP is will also provide technical training on topics such as sustainable farming practices, quality control, and business practices.
Study NCT03210454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intimate Partner Violence (IPV) Prevention Training
Description: IPV prevention training involves 24 hours of gender training (gender equality and rights, economic empowerment, gender-based violence prevention), and 8 hours of nutrition and food security training (with a focus on gender).
Study NCT00147485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-024322
Study NCT05334199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodegradable stent
Description: Bronchoscopic placement of biodegradable stent in patients with airway complications after lung transplant
Study NCT02995460 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interval training
Description: 4x4 high intensity interval training
Study NCT03498768 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Subjects will be invited to complete a detailed questionnaire regarding personal information, known risk factors for lung cancer and psychological status.
Study NCT00373529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Induction cycle 1: cycle 1 of clofarabine 30 mg/m\^2/day as a 1-hour intravenous infusion for 5 consecutive days.~Reinduction (cycle 2) and/or Consolidation cycles (cycles 2-6): cycles repeated minimally every 28 days, of clofarabine 20 mg/m\^2/day as a 1-hour intravenous infusion for 5 consecutive days.
Study NCT04165967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of TIL Transfer with anti-PD-1 Therapy and low dose IL-2
Description: The study uses a personalized IMP, i.e. TIL product and in combination with IL-2 treatment and nivolumab.~Day 0: Autologous TIL: (minimum 5 x 109 and up to a maximum of 2 x 1011 lymphocytes) administered intravenously over 20 to 30 minutes.~Day 0: Interleukin-2 (Proleukin): 125.000 IU/kg/day s.c. for maximum 12 days as inpatients with a 2 days break after the first 4-5 doses (maximum 10 days dosing). Actual body weight will be used in calculating the dose of interleukin-2.~Starting Day 14: Nivolumab application 240 mg i.v. over 30 minutes ever 2 weeks with a maximum to 2 years, or until disease progression or inacceptable toxicity.
Study NCT03071081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOP1288
Description: Oral TOP1288
Study NCT03071081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to TOP1288
Description: Oral placebo to TOP1288
Study NCT00570882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib 4/2
Description: Sunitinib 50 mg PO 4 weeks followed by 2 week rest
Study NCT03050203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: custom pack
Description: Preparation of the surgical field using a custom pack. The use of a custom pack provides much of the material provided for the preparation of the surgical field with a single opening of the package , reducing the risk of contamination of the material.
Study NCT03050203 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: The scrub nurse prepares the surgical field opening all the sterile packs it deems necessary for the surgery
Study NCT03512951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital signal processing algorithms
Description: The intervention consists in applying five processing on some recorded speech signals. In particular, the processing performed by one specific algorithm is compared against the four other. The applied processing is supposed to restore sound externalization (expected audio-visual fusion).
Study NCT05320341 — intervention group
Intervention type: PROCEDURE
Intervention: TIVA
Description: During the anesthesia maintenance of the TIVA group, 3 μg.kg-1 fentanyl, 0.01-0.05 mg.kg-1 midazolam, and 0.2 mg.kg-1 rocuronium bromide were applied throughout the operation to keep BIS between 40 and 60, approximately once every 45 minutes.
Study NCT05320341 — intervention group
Intervention type: PROCEDURE
Intervention: SEVO
Description: During the anesthesia maintenance of the SEVO group, 2-3% sevoflurane (1-2 MAC), 3 μg.kg-1 fentanyl and 0.2 mg.kg-1 rocuronium bromide were applied throughout the operation to keep BIS between 40-60.
Study NCT02664233 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile and connected health
Description: Patients will use a smart phone and a fitness tracker for self-monitoring of diet and physical activity for 3 months; 3) Smart phones will provide feedback with graphical presentation of self-monitored information to patients; 4) Patient self-monitored information will be integrated into Chronicle Diabetes, so that educators will be able to view this information and give feedback in a follow-up visit.
Study NCT02823652 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard genetic education
Description: Undergo usual care
Study NCT02823652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Counseling
Description: Complete remote counseling
Study NCT02823652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Testing
Description: Undergo germline testing
Study NCT02823652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Complete on-line genetic education
Study NCT02823652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT02823652 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT03077321 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARE plus Peer Mentor
Description: A parent who has completed the standard CARE program will be recruited to be a peer mentor. The peer mentor will attend the CARE training for group leaders and will also be trained in motivational interviewing. These skills will then be used strategically in weekly phone discussions between the peer mentor and parent about practicing the CARE parenting skills in the home setting and planning for attending the 6 training sessions. The parent mentor will co-facilitate the CARE groups in the peer mentor arm along with 2 additional CARE therapists. The peer mentor will also call the parents in the peer mentor arm before each session to discuss progress on homework, and to address barriers for program attendance.
Study NCT03077321 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CARE
Description: CARE involves 6 weekly 90-minute sessions administered to 6-10 parents by 2 therapists. The initial phase focuses on developing parenting skills aimed at increasing attention to children's pro-social behaviors while ignoring minor attention seeking misbehaviors. The second phase teaches techniques for giving children effective commands in order to set age-appropriate limits and increase compliance. Children do not attend the training but parents are expected to practice the skills with their children between sessions.
Study NCT03656874 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support
Description: The clinical decision support will provide clinical practice guideline-supported, evidence-based, and personalized scripts that are tailored based on patients' self-reported smoking attributes to deliver interventions consistent with the standard of care
Study NCT00788502 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healing Touch
Study NCT00788502 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Desensitization Therapy
Study NCT04158960 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Equine-assisted activities
Description: Participants performed riding-related activities on and off of a horse once per week for 8 weeks
Study NCT04158960 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GaitWay program
Description: Participants performed riding-related activities on and off of a horse, along with brain-building activities including balance tasks, swinging, spinning, music therapy, and sensory tasks, all once per week for 8 weeks
Study NCT02023736 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systemic Therapy Inventory of Change (STIC)
Description: The STIC is a computerized measurement and feedback system for use in psychotherapy. The measurement system consists of weekly questionnaires, completed on the computer, that target symptoms and functioning in a variety of domains of a clients life (e.g., individual symptoms, couple functioning, family functioning, relationship with children). The feedback system consists of a web-portal where therapists may access their clients' STIC responses, for the purposes of planning treatment, assessing progress, and discussing change with clients.
Study NCT02023736 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Clients receive psychotherapy treatment as planned and implemented by their psychotherapists. Exact type of treatment varies by therapist and according to client need.
Study NCT02023736 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Clients receive psychotherapy treatment as planned and implemented by their psychotherapists. Exact type of treatment varies by therapist and according to client need.
Study NCT01475084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryobiopsy (Autoclavable cryoprobe 20416-032 (ERBE, Germany) Flexible FB-55CD-1 Olympus forceps
Description: The tip of the cryoprobe will be attached to suspicious part of parietal pleura and activated by footswitch for 3 seconds. The frozen tissue is going to be extracted by gently pulling of the probe. The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar. The biopsy sample will be released from the probe by thawing in the saline.~Forceps biopsy will be performed on usual way.
Study NCT00534014 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin C
Description: Arm A = 0 mg Vitamin C, Arm B = 250 mg Vitamin C, Arm C = 500 mg Vitamin C, Arm D = 1000 mg Vitamin C
Study NCT02498717 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GameReady
Description: Cryotherapy and compression
Study NCT00534014 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Arm A = 0 mg Vitamin C, Arm B = 250 mg Vitamin C, Arm C = 500 mg Vitamin C, Arm D = 1000 mg Vitamin C
Study NCT04058574 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Proprioception measurement on isokinetic dynamometer
Description: Proprioception measurement on isokinetic dynamometer using joint position sense (JPS) and the threshold to detection of passive motion (TTDPM)
Study NCT04058574 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Proprioception measurement on isokinetic dynamometer
Description: Proprioception measurement on isokinetic dynamometer using joint position sense (JPS) and the threshold to detection of passive motion (TTDPM)
Study NCT01521065 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRay
Description: Approved dose of Anti-VEGF injection given at Day 0 followed by treatment with 16 Gy dose of IRay up to 14 days later.
Study NCT00885521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 8 week, twice weekly exercise program with endurance and upper and lower limb strength training
Study NCT01330420 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Response Resiliency Program for Depression
Description: The program combines lecture, skills training, symptom monitoring, and group sharing aimed at preparing patients to take active roles in managing their own health. Elements of the program include:~* Elicitation of the relaxation response through techniques such as diaphragmatic breathing and mindfulness.~* Examination and reversal of negative thought patterns.~* Physical movement, including stretching and yoga.~* Healthy eating and other positive lifestyle behaviors.~* Goal setting.
Study NCT04188314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: The intervention group will receive desflurane for maintenance of anaesthesia, and the quality of recovery score will be compared post-operatively with the control group who received isoflurane.